{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:05:15Z","timestamp":1785243915585,"version":"3.55.0"},"reference-count":180,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, with poor survival driven by late presentation, aggressive tumor biology, and limited responsiveness to conventional systemic therapy. Advances in molecular profiling have expanded opportunities for biomarker-guided and targeted therapeutic approaches. Methods: A literature review was conducted using PubMed and the Cochrane Library through July 2026, supplemented by abstracts and proceedings from major international oncology conferences. Results: Pancreatic cancer is driven mainly by somatic changes in KRAS, TP53, CDKN2A, and SMAD4. Established precision approaches include maintenance olaparib for selected platinum-sensitive tumors with germline BRCA1 or BRCA2 pathogenic variants, immune checkpoint inhibition for mismatch repair-deficient or microsatellite instability-high tumors, and tropomyosin receptor kinase inhibition for cancers with neurotrophic tyrosine receptor kinase gene fusions. Direct inhibition of KRAS and RAS represents a major therapeutic breakthrough. KRAS G12C inhibitors established proof of concept, while agents targeting the more common KRAS G12D mutation are showing encouraging early activity. In the randomized phase III RASolute 302 trial, the multiselective RAS inhibitor daraxonrasib improved survival compared with chemotherapy in previously treated metastatic disease with oncogenic RAS mutations. Early studies of zoldonrasib combinations have extended this progress to KRAS G12D-mutant disease, although confirmation is required. Molecular profiling, next-generation sequencing, patient-derived organoids, and circulating tumor DNA may further improve treatment selection and monitoring. Conclusions: Precision oncology is becoming clinically relevant in pancreatic ductal adenocarcinoma. KRAS- and RAS-directed therapies are central advances, but resistance, toxicity, limited durability, and access to comprehensive testing remain important challenges.<\/jats:p>","DOI":"10.3390\/curroncol33080452","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:45:26Z","timestamp":1785239126000},"page":"452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5593-3456","authenticated-orcid":false,"given":"Ramy","family":"Habib","sequence":"first","affiliation":[{"name":"School of Medicine, University of Limerick, Limerick V94 T9PX, Munster, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6443-4059","authenticated-orcid":false,"given":"Erika","family":"Arnold","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Limerick, Limerick V94 T9PX, Munster, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasin","family":"Obi","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-5207","authenticated-orcid":false,"given":"Franco J.","family":"Vizeacoumar","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"},{"name":"Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2099-698X","authenticated-orcid":false,"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"},{"name":"Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"ref_3","first-page":"e70043","article-title":"Cancer Statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_5","unstructured":"National Cancer Institute (2026, June 02). Cancer Stat Facts: Pancreatic Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.pan.2024.07.017","article-title":"Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma\u2014A retrospective analysis of 272 patients","volume":"24","author":"Brunner","year":"2024","journal-title":"Pancreatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104528","DOI":"10.1016\/j.esmoop.2025.104528","article-title":"ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer","volume":"10","author":"Conroy","year":"2025","journal-title":"ESMO Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00432-020-03332-5","article-title":"Immunological combination treatment holds the key to improving survival in pancreatic cancer","volume":"146","author":"Sodergren","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: From state-of-the-art treatments to promising novel therapies","volume":"12","author":"Hidalgo","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JOP.2016.015586","article-title":"Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck with Cytotoxic Chemotherapy?","volume":"12","author":"Varadhachary","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_16","first-page":"128","article-title":"Tumor microenvironment and progression of pancreatic cancer","volume":"32","author":"Erkan","year":"2010","journal-title":"Exp. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1126\/science.1175940","article-title":"Breaching the Cancer Fortress","volume":"324","author":"Olson","year":"2009","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00535-009-0013-2","article-title":"Signal transduction in pancreatic stellate cells","volume":"44","author":"Masamune","year":"2009","journal-title":"J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pan.2012.12.058","article-title":"Pancreatic stellate cells\u2014Multi-functional cells in the pancreas","volume":"13","author":"Masamune","year":"2013","journal-title":"Pancreatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): An update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","article-title":"Mutations in key driver genes of pancreatic cancer: Molecularly targeted therapies and other clinical implications","volume":"42","author":"Hu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_23","unstructured":"National Comprehensive Cancer Network (2025). NCCN Guidelines for Patients: Pancreatic Cancer, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/pancreatic-patient.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17562848231171456","DOI":"10.1177\/17562848231171456","article-title":"The role of molecular testing in pancreatic cancer","volume":"16","author":"Zhen","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Llach, J., Luzko, I., Earl, J., Barreto, E., Rodr\u00edguez-Garrote, M., Lleix\u00e0, M., Herrera-Pariente, C., Fern\u00e1ndez, G., Munoz, J., and Bonjoch, L. (2024). Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study. Cancers, 16.","DOI":"10.2139\/ssrn.4888402"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Blanco Abad, C., Pons, P.G., Ram\u00edrez, S.C., Alejandro, M.\u00c1., Torres, I., Miramar, D., \u00c1lvarez, S.I., Marques, E.P., and Cid, R.P. (2025). Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020367"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100709","DOI":"10.1016\/j.modpat.2025.100709","article-title":"Germline Pathogenic Variants in Patients with Pancreatic Ductal Adenocarcinoma and Extra-Pancreatic Malignancies: A Nationwide Database Analysis","volume":"38","author":"Kryklyva","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of Germline Genetic Testing Panels in Patients with Cancer: ASCO Guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41525-023-00374-9","article-title":"Clinically significant germline pathogenic variants are missed by tumor genomic sequencing","volume":"8","author":"Stout","year":"2023","journal-title":"npj Genom. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma (The Cancer Genome Atlas Research Network)","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Taherian, M., Wang, H., and Wang, H. (2022). Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. Cells, 11.","DOI":"10.3390\/cells11193068"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/1878-0261.13576","article-title":"Molecular characteristics of early-onset pancreatic ductal adenocarcinoma","volume":"18","author":"Debernardi","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153303382092096","DOI":"10.1177\/1533033820920969","article-title":"The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment","volume":"19","author":"Sun","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nusrat, F., Khanna, A., Jain, A., Jiang, W., Lavu, H., Yeo, C.J., Bowne, W., and Nevler, A. (2024). The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13072103"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.21037\/hbsn.2018.07.03","article-title":"Increased mutant KRAS gene dosage drives pancreatic cancer progression: Evidence for wild-type KRAS as a tumor suppressor?","volume":"7","author":"Kent","year":"2018","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kumar, P.A., Serinelli, S., Zaccarini, D.J., Huang, R., Danziger, N., Janovitz, T., Basnet, A., Sivapiragasam, A., Graziano, S., and Ross, J.S. (2023). Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1169586"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1158\/1078-0432.CCR-22-3930","article-title":"Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer","volume":"29","author":"Singh","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101539","DOI":"10.1016\/j.esmoop.2023.101539","article-title":"Smaller panel, similar results: Genomic profiling and molecularly informed therapy in pancreatic cancer","volume":"8","author":"Reissig","year":"2023","journal-title":"ESMO Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/PO.20.00265","article-title":"Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer","volume":"5","author":"Fusco","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-12-1215","article-title":"Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors","volume":"18","author":"Yachida","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/cncr.33038","article-title":"Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma","volume":"126","author":"McIntyre","year":"2020","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17588359241290482","DOI":"10.1177\/17588359241290482","article-title":"Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX","volume":"16","author":"Kim","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10020-020-00183-1","article-title":"A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients","volume":"26","author":"Saha","year":"2020","journal-title":"Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cimb46040177","article-title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer","volume":"46","author":"Stefanoudakis","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","article-title":"The pancreatic cancer genome revisited","volume":"18","author":"Hayashi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Llach, J., Aguilera, P., S\u00e1nchez, A., Gin\u00e8s, A., Fern\u00e1ndez-Esparrach, G., Soy, G., Sendino, O., Vaquero, E., Carballal, S., and Ausania, F. (2023). Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in CDKN2A. Cancers, 15.","DOI":"10.3390\/cancers15061690"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e71137","DOI":"10.7554\/eLife.71137","article-title":"Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance","volume":"11","author":"Kimura","year":"2022","journal-title":"eLife"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kawanaka, Y., Inagaki, C., Okura, M., Mitani, S., Takahama, T., Yonesaka, K., Chiba, Y., Nakagawa, K., Kawakami, H., and Hayashi, H. (2025). Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinoma. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1570731"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MPA.0000000000001145","article-title":"Pancreatitis-Associated Genes and Pancreatic Cancer Risk: A Systematic Review and Meta-Analysis","volume":"47","author":"Cazacu","year":"2018","journal-title":"Pancreas"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105899","DOI":"10.1016\/j.esmoop.2025.105899","article-title":"Precision medicine strategy in pancreatic ductal adenocarcinoma","volume":"10","author":"Tarabay","year":"2025","journal-title":"ESMO Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.semradonc.2025.07.006","article-title":"Emerging Systemic Therapy Considerations for Pancreatic Cancer","volume":"35","author":"Liang","year":"2025","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e001925","DOI":"10.1136\/bmjgast-2025-001925","article-title":"Actionable mutations in pancreatic cancer: Where targeted therapies are making a difference","volume":"12","author":"Fivaz","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation","volume":"41","author":"Yaeger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pradeep, R., Isbeih, N.J., Abraham, F.F., Noori, E., Yeung, Z.P., and Kundranda, M.N. (2026). KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020873"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Krupa, K., Fudalej, M., Miski, H., W\u0142oszek, E., Szymczak, M., Badowska-Kozakiewicz, A., Czerw, A., and Dept\u0105\u0142a, A. (2025). KRAS-Wild Pancreatic Cancer\u2014More Targets than Treatment Possibilities?. Cancers, 17.","DOI":"10.3390\/cancers17233769"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e191939","DOI":"10.1172\/JCI191939","article-title":"KRAS: The Achilles\u2019 heel of pancreas cancer biology","volume":"135","author":"Talabi","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of Maintenance Rucaparib in Patients with Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","article-title":"DNA damage repair as a target in pancreatic cancer: State-of-the-art and future perspectives","volume":"70","author":"Perkhofer","year":"2021","journal-title":"Gut"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00115","article-title":"Outcomes in Patients with Pancreatic Adenocarcinoma with Genetic Mutations in DNA Damage Response Pathways: Results from the Know Your Tumor Program","volume":"3","author":"Pishvaian","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall Survival Results from the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dai, M., Sheng, J., Zhang, Q., Wang, J., Fu, Q., and Liang, T. (2023). Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1118633"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wolpin, B.M., Pant, S., Spira, A., Biachi de Castria, T., Botta, G.P., Florou, V., Manji, G., Opsipov, A., Pelster, M., and Sen, S. (2026, January 1\u20134). Safety and Efficacy of Zoldonrasib (RMC-9805) plus Chemotherapy in Patients with First-Line RAS G12D Metastatic Pancreatic Adenocarcinoma. Proceedings of the ESMO Gastrointestinal Cancers Congress 2026, Munich, Germany. Abstract 340O.","DOI":"10.1016\/j.annonc.2026.05.381"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Azad, N.S., Kim, D., Oberstein, P., Mannion, B., Pelster, M., Ng, K., Yaeger, R., Kim, E.J.-H., Papadopoulos, K., and Lorusso, P.M. (2026, January 1\u20134). Safety and Efficacy of Zoldonrasib (RMC-9805) plus Daraxonrasib (RMC-6236) in Patients with Second-Line or Later KRAS G12D Metastatic Pancreatic Adenocarcinoma. Proceedings of the ESMO Gastrointestinal Cancers Congress 2026, Munich, Germany. Abstract 341O.","DOI":"10.1016\/j.annonc.2026.05.382"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.soncn.2014.05.002","article-title":"Science and Mechanism of Action of Targeted Therapies in Cancer Treatment","volume":"30","author":"Wujcik","year":"2014","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the Immune System: The History and Background of Immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-022-00346-5","article-title":"Personalized matched targeted therapy in advanced pancreatic cancer: A pilot cohort analysis","volume":"8","author":"Shaya","year":"2023","journal-title":"npj Genom. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Li, B., Zhang, Q., Castaneda, C., and Cook, S. (2024). Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102175"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100638","DOI":"10.1016\/j.esmoop.2022.100638","article-title":"Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?","volume":"7","author":"Pellat","year":"2022","journal-title":"ESMO Open"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-16-2319","article-title":"Current and Emerging Therapies in Metastatic Pancreatic Cancer","volume":"23","author":"Manji","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40169-019-0221-1","article-title":"Pancreatic cancer microenvironment: A current dilemma","volume":"8","author":"Uzunparmak","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14737140.2024.2357802","article-title":"The trend toward more target therapy in pancreatic ductal adenocarcinoma","volume":"24","author":"Deiana","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Leroux, C., and Konstantinidou, G. (2021). Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers, 13.","DOI":"10.3390\/cancers13040799"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"Wainberg","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11864-023-01174-0","article-title":"Targeting BRCA and PALB2 in Pancreatic Cancer","volume":"25","author":"Anbil","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2024.42.3_suppl.661","article-title":"A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update","volume":"42","author":"Reiss","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_99","unstructured":"Wolpin, B.M., Musher, B.L., Manji, G.A., Park, W., Spira, A., Azad, N., Florou, V., De Castria, T.B., O\u2019Hara, M.H., and Borazanci, E. (2026, January 17\u201322). Daraxonrasib plus chemotherapy as first-line treatment for patients with metastatic pancreatic adenocarcinoma. Proceedings of the 2026 AACR Annual Meeting, San Diego, CA, USA. Abstract LB407\/7."},{"key":"ref_100","unstructured":"National Library of Medicine (2026, July 13). Study of Zoldonrasib Plus Investigator\u2019s-Choice Chemotherapy Versus Placebo Plus Investigator\u2019s-Choice Chemotherapy as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 305), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07621718."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Principe, D.R. (2022). Precision Medicine for BRCA\/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. Cancers, 14.","DOI":"10.3390\/cancers14040897"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10555-021-09983-1","article-title":"Targeting DNA damage repair pathways in pancreas cancer","volume":"40","author":"Crowley","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2023.11.001","article-title":"Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer","volume":"51","author":"LaRose","year":"2024","journal-title":"Semin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","article-title":"BRCA1\/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma","volume":"226","author":"Blair","year":"2018","journal-title":"J. Am. Coll. Surg."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Mekonnen, N., Yang, H., and Shin, Y.K. (2022). Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.880643"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4","article-title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial","volume":"37","author":"Kindler","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yang, Z.-Y., Yuan, J.-Q., Di, M.-Y., Zheng, D.-Y., Chen, J.-Z., Ding, H., Wu, X.-Y., Huang, Y.-F., Mao, C., and Tang, J.-L. (2013). Gemcitabine plus erlotinib for advanced pancreatic cancer: A systematic review with meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057528"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4240\/wjgs.v16.i3.921","article-title":"Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis","volume":"16","author":"Liu","year":"2024","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2016.67.1412","article-title":"Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Sohal","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdz385","article-title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","volume":"30","author":"Hechtman","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","article-title":"JSCO\u2013ESMO\u2013ASCO\u2013JSMO\u2013TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: Is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_115","unstructured":"Arbour, K.C., Pubnkar, S.R., Garrido-Laguna, I., Hong, D.S., Wolpin, B., Pelster, M.S., Barve, M., Starodub, A., Sommerhalder, D., and Chang, S. (2023, January 20\u201324). Preliminary clinical activity of RMC-6236, a first-in-class RAS(ON) multi-selective tri-complex inhibitor, in patients with RAS-mutant solid tumors. Proceedings of the ESMO Congress 2023, Madrid, Spain."},{"key":"ref_116","unstructured":"O\u2019Reilly, E.M., Wolpin, B., Pant, S., Hecht, J.R., Valerin, J., Kim, D.W., Azad, N., Aung, K., Tao, L., and Kar, S. (2026, January 17\u201322). Daraxonrasib monotherapy as first-line treatment for patients with metastatic pancreatic adenocarcinoma. Proceedings of the 2026 AACR Annual Meeting, San Diego, CA, USA. Abstract LB337\/18."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Garcia-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., and Acedo, P. (2021). The State-of-the-Art of Phase II\/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040566"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13543784.2019.1632289","article-title":"Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)","volume":"28","author":"Babiker","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine Plus Bevacizumab Compared with Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III Trial of Bevacizumab in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer","volume":"27","author":"Vervenne","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s10637-011-9687-4","article-title":"A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy","volume":"30","author":"Bodoky","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","article-title":"Effect of Selumetinib and MK-2206 vs. Oxaliplatin and Fluorouracil in Patients with Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial","volume":"3","author":"Chung","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","article-title":"Oral mTOR Inhibitor Everolimus in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer","volume":"27","author":"Wolpin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00280-015-2730-y","article-title":"Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer","volume":"75","author":"Kordes","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel\/Gemcitabine Versus Nab-Paclitaxel\/Gemcitabine in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2020.38.4_suppl.638","article-title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa with Nab-Paclitaxel Plus Gemcitabine for Patients with Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Tempero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized Phase III Study of FOLFOX Alone or with Pegilodecakin as Second-Line Therapy in Metastatic Pancreatic Cancer (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Smith, J.P., Nkulikiyimana, G.C., Cao, H., Chen, W., Kallakury, B., Kwagyan, J., Duttargi, A., and Weinberg, B.A. (2026). Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18030379"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/bies.201600070","article-title":"Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success","volume":"38","author":"Halsall","year":"2016","journal-title":"BioEssays"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","article-title":"Translational advances in pancreatic ductal adenocarcinoma therapy","volume":"3","author":"Hosein","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: Anti-PD-(L)1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40265-020-01304-0","article-title":"New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma","volume":"80","author":"Singh","year":"2020","journal-title":"Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer\u2014Clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and Opportunities for Pancreatic Cancer Immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_141","unstructured":"National Library of Medicine (2026, June 02). Short-Course Versus Long-Course Pre-Operative Chemotherapy with mFOLFIRINOX or PAXG (CASSANDRA TRIAL), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04793932."},{"key":"ref_142","unstructured":"National Library of Medicine (2026, June 02). Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04927780."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e007586","DOI":"10.1136\/jitc-2023-007586","article-title":"Multicenter Randomized Controlled Trial of Neoadjuvant Chemoradiotherapy Alone or in Combination with Pembrolizumab in Patients with Resectable or Borderline-Resectable Pancreatic Adenocarcinoma","volume":"11","author":"Katz","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/s41467-026-68976-2","article-title":"Neoadjuvant Modified FOLFIRINOX plus Nivolumab in Borderline-Resectable Pancreatic Ductal Adenocarcinoma: A Pilot Phase 1 Trial","volume":"17","author":"Wainberg","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"100134","DOI":"10.1016\/j.esmogo.2025.100134","article-title":"A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer","volume":"7","author":"Hussung","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/s41467-025-60808-z","article-title":"Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial","volume":"16","author":"Knox","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Dubrovsky, G., Ross, A., Jalali, P., and Lotze, M. (2024). Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011013"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Bendari, A., Vele, O., Baskovich, B., Bendari, A., Sebika, M., Gomez Marti, J.L., Krishnamurthy, K., and Asiry, S. (2025). Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions. Gastroenterol. Insights, 16.","DOI":"10.3390\/gastroent16040039"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Cox, M., Vitello, D., and Chawla, A. (2025). Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1520717"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Ojha, S., Sessions, W., Zhou, Y., and Aung, K.L. (2025). ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110589"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e2531373","DOI":"10.1001\/jamanetworkopen.2025.31373","article-title":"Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors","volume":"8","author":"Mahadevia","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/tgh-24-167","article-title":"Prognostic and monitoring potential of circulating tumor DNA in resectable pancreatic cancer","volume":"10","author":"Labori","year":"2025","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Juthani, R., and Manne, A. (2025). Blood-based biomarkers in pancreatic ductal adenocarcinoma: Developments over the last decade and what holds for the future\u2014A review. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1555963"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.gde.2019.02.003","article-title":"Organoid models for translational pancreatic cancer research","volume":"54","author":"Tiriac","year":"2019","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Dong, H., Vizeacoumar, F.S., Smith, J., Jette, N., Price, J.D.W., Maranda, V., Gong, L., Freywald, T., Vizeacoumar, J.P., and Lazell-Wright, M. (2025). Organoid pharmacotyping of pancreatic cancer enables functional precision oncology and drug repurposing. bioRxiv.","DOI":"10.64898\/2025.12.01.691211"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1158\/1078-0432.CCR-20-4116","article-title":"Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer","volume":"28","author":"Grossman","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ueg2.12701","article-title":"Organoid-based precision medicine in pancreatic cancer","volume":"13","author":"Beutel","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"360","DOI":"10.6004\/jnccn.2024.7050","article-title":"Molecular Tests in Pancreatic Cancer: Critical Role of Molecular Testing, Expanding Access, and Adherence to the NCCN Guidelines for Pancreatic Cancer","volume":"22","author":"Jhala","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"116065","DOI":"10.1016\/j.ejca.2025.116065","article-title":"Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study","volume":"230","author":"Strijk","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/eus.0000000000000097","article-title":"Adequacy of EUS\u2013guided fine-needle aspiration and fine-needle biopsy for next-generation sequencing in pancreatic malignancies: A systematic review and meta-analysis","volume":"13","author":"Pan","year":"2024","journal-title":"Endosc. Ultrasound"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/labmed\/lmac046","article-title":"Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma","volume":"54","author":"Petersen","year":"2023","journal-title":"Lab. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/curroncol31030103","article-title":"Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada","volume":"31","author":"Snow","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e70117","DOI":"10.1002\/jgc4.70117","article-title":"Assessment of barriers to pancreatic cancer surveillance in high-risk individuals","volume":"34","author":"Snyder","year":"2025","journal-title":"J. Genet. Couns."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_166","unstructured":"National Library of Medicine (2026, June 02). Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06608927."},{"key":"ref_167","unstructured":"National Library of Medicine (2026, June 02). A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer (DIRECT), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03899636."},{"key":"ref_168","unstructured":"National Library of Medicine (2026, June 02). Adjuvant Trial in Patients with Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05314998."},{"key":"ref_169","unstructured":"National Library of Medicine (2026, June 02). Chiauranib Plus PD-1 Inhibitor, Albumin-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Ductal Adenocarcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07445295."},{"key":"ref_170","unstructured":"National Library of Medicine (2026, June 02). A Phase III, Randomized, Clinical Trial of GnP Combined with SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients with Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006\/ICSBR-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07336953."},{"key":"ref_171","unstructured":"National Library of Medicine (2026, June 02). A Study Comparing BMS-986504 in Combination with Nab-Paclitaxel and Gemcitabine Versus Placebo in Combination with Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma with Homozygous MTAP Deletion (MountainTAP-30), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07076121."},{"key":"ref_172","unstructured":"National Library of Medicine (2026, June 02). Safety and Efficacy of Immuncell-LC with Gemcitabine in Resectable Pancreatic Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04969731."},{"key":"ref_173","unstructured":"National Library of Medicine (2026, June 02). A Study of OT-101 with mFOLFIRINOX in Patients with Advanced and Unresectable or Metastatic Pancreatic Cancer (STOP-PC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06079346."},{"key":"ref_174","unstructured":"National Library of Medicine (2026, June 02). Study of Daraxonrasib and Daraxonrasib + GnP as First-Line Treatment in Patients with Metastatic Pancreatic Adenocarcinoma (RASolute 303), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07491445."},{"key":"ref_175","unstructured":"National Library of Medicine (2026, June 02). Clinical Trial Comparing TQB2868 Injection Combined with Anlotinib Hydrochloride Capsules with Placebo Combined with Chemotherapy as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07165951."},{"key":"ref_176","unstructured":"National Library of Medicine (2026, June 02). Study of Daraxonrasib (RMC-6236) in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07252232."},{"key":"ref_177","unstructured":"National Library of Medicine (2026, June 02). Study of Nab-Paclitaxel and Gemcitabine with or Without SBP-101 in Pancreatic Cancer (ASPIRE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05254171."},{"key":"ref_178","unstructured":"National Library of Medicine (2026, June 02). Study of NABPLAGEM vs. Nab-Paclitaxel\/Gemcitabine in BRCA1\/2 or PALB2 Pancreatic Cancer (PLATINUM-CAN), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06783140."},{"key":"ref_179","unstructured":"National Library of Medicine (2026, June 02). A Study to Evaluate Chemotherapy with or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07522073."},{"key":"ref_180","unstructured":"National Library of Medicine (2026, June 02). Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06958328."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:23:18Z","timestamp":1785241398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":180,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080452"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080452","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}